Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen-Specific T Cells (MT-601) Administered to Patients With Relapsed or Refractory Non-Hodgkin and Hodgkin Lymphoma (APOLLO)

NCT05798897 is registered in ClinicalTrials.gov with Marker Therapeutics, Inc. as lead sponsor.

NCT NCT05798897
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05798897 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen-Specific T Cells (MT-601) Administered to Patients With Relapsed or Refractory Non-Hodgkin and Hodgkin Lymphoma (APOLLO)
Lead sponsor
Marker Therapeutics, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
January 2, 2023
Completion date
February 28, 2028
Enrollment
79 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin lymphoma, hodgkin lymphoma, adult, hodgkin's lymphoma, relapsed, adult, non hodgkin lymphoma, non-hodgkin lymphoma, adult, non-hodgkin lymphoma, refractory, non-hodgkin lymphoma, relapsed